CSIR and Mylan join hands

CSIR and Mylan join hands to develop potential COVID-19 therapies  

CSIR and Mylan Laboratories revealed a collaboration under which CSIR’s constituent laboratory CSIR-IICT – Indian Institute of Chemical Modern Technology and Mylan Laboratories will work together to determine potential therapies against COVID-19 infection.

As part of this partnership, a set of clinical trials will be carried out in the direction of new and innovative remedies to manage the COVID-19 pandemic in India. The initial clinical trials to be started is a multiple arm stage 3 study that will be carried out in adult COVID -19 patients having mild to modest infection.

The request for the clinical trials has been given to the Drugs Controller General of India for regulative approvals.

Dr. Ram Vishwakarma, Honorary Advisor to Director General-CSIR, and Ex-Director of CSIR-Indian Institute of Integrative Medication will be leading this project, according to CSIR.

The existing partnership with Mylan Laboratories is a considerable milestone and during the ongoing pandemic. Council of Scientific & Industrial Research has prioritized carrying out  clinical trials of well-proven medicines in collaboration with industry towards the development of various restorative alternatives for against SARS-CoV-2, said Dr. Shehkar C Mande, Director General of CSIR

CSIR is delighted

to join hands with Mylan Laboratories as a knowledge and scientific partner. The team expects to work with the firm, particularly given Mylan’s large market experience in commercialization and clinical trials, said Dr, Chandrasekhar, Director of CSIR-IICT.

The partnership with CSIR is an imperative measure focused on recognizing effective treatments for COVID-19 patients. Along with bringing up new implications, this collaboration will additionally aid us to identify multiple molecules that can possibly be used in future therapies for multiple other infectious diseases, said Sanjeev Sethi, Chief Operating Officer, Mylan Laboratories.


CSIR and Mylan join hands to develop potential COVID-19 therapies  

Author: Sruthi S